These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 33384662)

  • 1. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies.
    Luci C; Bourinet M; Leclère PS; Anty R; Gual P
    Front Endocrinol (Lausanne); 2020; 11():597648. PubMed ID: 33384662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
    Mridha AR; Haczeyni F; Yeh MM; Haigh WG; Ioannou GN; Barn V; Ajamieh H; Adams L; Hamdorf JM; Teoh NC; Farrell GC
    Clin Sci (Lond); 2017 Aug; 131(16):2145-2159. PubMed ID: 28687713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating inflammation to combat non-alcoholic fatty liver disease.
    Wiering L; Tacke F
    J Endocrinol; 2023 Jan; 256(1):. PubMed ID: 36259984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis.
    Overi D; Carpino G; Franchitto A; Onori P; Gaudio E
    Cells; 2020 Mar; 9(3):. PubMed ID: 32131439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack.
    Oates JR; McKell MC; Moreno-Fernandez ME; Damen MSMA; Deepe GS; Qualls JE; Divanovic S
    Front Immunol; 2019; 10():2893. PubMed ID: 31921154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triggering and resolution of inflammation in NASH.
    Schuster S; Cabrera D; Arrese M; Feldstein AE
    Nat Rev Gastroenterol Hepatol; 2018 Jun; 15(6):349-364. PubMed ID: 29740166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural Killer Cells and Type 1 Innate Lymphoid Cells Are New Actors in Non-alcoholic Fatty Liver Disease.
    Luci C; Vieira E; Perchet T; Gual P; Golub R
    Front Immunol; 2019; 10():1192. PubMed ID: 31191550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease.
    Katsarou A; Moustakas II; Pyrina I; Lembessis P; Koutsilieris M; Chatzigeorgiou A
    World J Gastroenterol; 2020 May; 26(17):1993-2011. PubMed ID: 32536770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH).
    Nati M; Haddad D; Birkenfeld AL; Koch CA; Chavakis T; Chatzigeorgiou A
    Rev Endocr Metab Disord; 2016 Mar; 17(1):29-39. PubMed ID: 26847547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
    Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
    J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis.
    Li H; Zhou Y; Wang H; Zhang M; Qiu P; Zhang M; Zhang R; Zhao Q; Liu J
    Front Immunol; 2020; 11():1169. PubMed ID: 32670278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipose tissue-derived stem cells prevent fibrosis in murine steatohepatitis by suppressing IL-17-mediated inflammation.
    Yamato M; Sakai Y; Mochida H; Kawaguchi K; Takamura M; Usui S; Seki A; Mizukoshi E; Yamashita T; Yamashita T; Ishida K; Nasti A; Tuyen HTB; Komura T; Yoshida K; Wada T; Honda M; Kaneko S
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1432-1440. PubMed ID: 30828861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease.
    Hundertmark J; Krenkel O; Tacke F
    Front Immunol; 2018; 9():2418. PubMed ID: 30405618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
    Farrell GC; Haczeyni F; Chitturi S
    Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrin β
    Guo Q; Furuta K; Lucien F; Gutierrez Sanchez LH; Hirsova P; Krishnan A; Kabashima A; Pavelko KD; Madden B; Alhuwaish H; Gao Y; Revzin A; Ibrahim SH
    J Hepatol; 2019 Dec; 71(6):1193-1205. PubMed ID: 31433301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
    Ibrahim SH; Hirsova P; Gores GJ
    Gut; 2018 May; 67(5):963-972. PubMed ID: 29367207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease.
    Zhou L; Shen H; Li X; Wang H
    Front Immunol; 2022; 13():951406. PubMed ID: 35958574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis.
    Kumar S; Duan Q; Wu R; Harris EN; Su Q
    Adv Drug Deliv Rev; 2021 Sep; 176():113869. PubMed ID: 34280515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.